Menu

European Medicines Agency to Move to Amsterdam

A coin toss decides the agency’s post-Brexit home once it departs from London.

Nov 20, 2017
Shawna Williams

ISTOCK, KARP85The European Medicines Agency (EMA), an organization that regulates drugs sold in the European Union for human and animal use, determined today (November 20) it will move from London to Amsterdam. The agency, which EU Observer reports employs 890 people, is making the move because of Britain’s decision to leave the E.U. in 2019. It has been based in London since 1995, the BBC reports.

Cities across Europe bid to be the new site for the EMA, which “promises to make its new host into a hub for Europe's medical industry,” the BBC notes. After three rounds of voting among EU ministers, Milan and Amsterdam were tied for the most votes, so the winner was decided by a coin toss. A vote on the new location for the European Banking Agency, also headquartered in London, is expected later today.

“The relocation of the E.M.A. away from London will be a bitter pill to swallow,” says Rory Palmer, a spokesperson for the UK Labour Party’s lawmakers in the European Parliament, in a statement to the New York Times. “Our economy will suffer. Our health sector will suffer. Our successful pharmaceutical industry will suffer.”

Halbe Zijlstra, the Netherlands’s foreign affairs minister, took a sunnier view, tweeting, “Good for the Netherlands and above all good for EU citizens who can continue to count on high-quality medicines & proper supervision. It shows we can tackle effects of Brexit with resolve.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!